Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors

Ruoyang Chen; Dawei Li; Ming Zhang; Xiaodong Yuan

doi:10.12659/AOT.933313

07 September 2021 : Original article

Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors

Ruoyang Chen^1BCEF, Dawei Li^1BCDFG, Ming Zhang^1AC, Xiaodong Yuan^1ADEF*

DOI: 10.12659/AOT.933313

Ann Transplant 2021; 26:e933313

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 1 Flow chart. A total of 837 people received kidney transplants during this period, of which 26 received HCV RNA(+) kidney transplants, and all recipients completed the follow-up. At the end of follow-up, HCV RNA was negative.

Back to the Article

Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors

Your Privacy